# Master Rollover Protocol for Continued Safety Assessment of Study Drug

> **NCT02632994** · — · AVAILABLE · sponsor: **Eli Lilly and Company**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** LY2503029
- **DRUG:** LY3023414
- **DRUG:** LY3838915
- **DRUG:** LY3847429

## Key facts

- **NCT ID:** NCT02632994
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632994, "Master Rollover Protocol for Continued Safety Assessment of Study Drug". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02632994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*